Biological treatments in behçet's disease: Beyond anti-TNF therapy

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Caso, Francesco ^a,b   Costa, Luisa ^c   Rigante, Donato ^d   Lucherini, Orso Maria ^a   Caso, Paolo ^e   Bascherini, Vittoria ^a   Frediani, Bruno ^a   Cimaz, Rolando ^f   Marrani, Edoardo ^f   Nieves Martín, Laura ^a,g   Atteno, Mariangela ^c   Raffaele, Carmela G L ^d   Tarantino, Giusyda ^d   Galeazzi, Mauro ^a   Punzi, Leonardo ^b   Cantarini, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GEVOKIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BEHCET DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; REVIEW; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BEHCET SYNDROME; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904690289     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/107421     Document Type: Review

References (87)

1. Rigante D., The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmunity Reviews 2012 11 5 348 356 2-s2.0-84857500409 10.1016/j.autrev.2011.10.008
2. International Study Group for Behcet's disease, Criteria for diagnosis of Behçet's disease. The Lancet 1990 335 1078 1080
3. Saadoun D., Wechsler B., Behçet's disease. Orphanet Journal of Rare Diseases 2012 7 1, article 20 2-s2.0-84859645480 10.1186/1750-1172-7-20
4. Direskeneli H., Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Annals of the Rheumatic Diseases 2001 60 11 996 1002 2-s2.0-0034757551 10.1136/ard.60.11.996 (Pubitemid 32990034)
5. Remmers E. F., Cosan F., Kirino Y., Ombrello M. J., Abaci N., Satorius C., Le J. M., Yang B., Korman B. D., Cakiris A., Aglar O., Emrence Z., Azakli H., Ustek D., Tugal-Tutkun I., Akman-Demir G., Chen W., Amos C. I., Dizon M. B., Kose A. A., Azizlerli G., Erer B., Brand O. J., Kaklamani V. G., Kaklamanis P., Ben-Chetrit E., Stanford M., Fortune F., Ghabra M., Ollier W. E. R., Cho Y.-H., Bang D., O'Shea J., Wallace G. R., Gadina M., Kastner D. L., Gül A., Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nature Genetics 2010 42 8 698 702 2-s2.0-77955087288 10.1038/ng.625
6. Kirino Y., Bertsias G., Ishigatsubo Y., Mizuki N., Tugal-Tutkun I., Seyahi E., Ozyazgan Y., Sacli F. S., Erer B., Inoko H., Emrence Z., Cakar A., Abaci N., Ustek D., Satorius C., Ueda A., Takeno M., Kim Y., Wood G. M., Ombrello M. J., Meguro A., Gül A., Remmers E. F., Kastner D. L., Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B51 and ERAP1. Nature Genetics 2013 45 2 202 207 2-s2.0-84873091770 10.1038/ng.2520
7. Maldini C., Lavalley M. P., Cheminant M., de menthon M., Mahr A., Relationships of HLA-B51 or B5 genotype with Behçet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology 2012 51 5 887 900 2-s2.0-84860231111 10.1093/rheumatology/ker428
8. Piga M., Mathieu A., Genetic susceptibility to Behçet's disease: role of genes belonging to the MHC region. Rheumatology 2011 50 2 299 310 2-s2.0-78751694700 10.1093/rheumatology/keq331 keq331
9. De Menthon M., LaValley M. P., Maldini C., Guillevin L., Mahr A., HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Care and Research 2009 61 10 1287 1296 2-s2.0-70349768117 10.1002/art.24642
10. Pineton de Chambrun M., Wechsler B., Geri G., Cacoub P., Saadoun D., New insights into the pathogenesis of Behçet's disease. Autoimmunity Reviews 2012 11 10 687 698 2-s2.0-84864385128 10.1016/j.autrev.2011.11.026
11. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A. M., Gul A., Houman M. H., Kötter I., Olivieri I., Salvarani C., Sfikakis P. P., Siva A., Stanford M. R., Stübiger N., Yurdakul S., Yazici H., Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Annals of the Rheumatic Diseases 2009 68 10 1528 1534 2-s2.0-70349378464 10.1136/ard.2008.087957
12. Cantarini L., Vitale A., Scalini P., Dinarello C. A., Rigante D., Franceschini R., Anakinra treatment in drug-resistant Behçet's disease: a case series. Clinical Rheumatology 2013 10.1007/s10067-013-2443-8
13. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A. M., Gul A., Houman M. H., Kötter I., Olivieri I., Salvarani C., Sfikakis P. P., Siva A., Stanford M. R., Stübiger N., Yurdakul S., Yazici H., EULAR recommendations for the management of Behçet disease. Annals of the Rheumatic Diseases 2008 67 12 1656 1662 2-s2.0-56749168836 10.1136/ard.2007. 080432
14. Dalvi S. R., Yildirim R., Yazici Y., Behcets syndrome. Drugs 2012 72 17 2223 2241 2-s2.0-84870006270 10.2165/11641370-000000000-00000
15. Aktulga E., Altaç M., Müftüoglu A., Ozyazgan Y., Pazarli H., Tüzün Y., A double blind study of colchicine in Behçet's disease. Haematologica 1980 65 399 402 (Pubitemid 11254772)
16. Yurdakul S., Mat C., Tüzün Y., Ozyazgan Y., Hamuryudan V., Uysal O., A double-blind trial of colchicine in Behçet's syndrome. Arthritis & Rheumatology 2001 44 2686 2692 (Pubitemid 33049346)
17. Davatchi F., Sadeghi Abdollahi B., Tehrani Banihashemi A., Shahram F., Nadji A., Shams H., Chams-Davatchi C., Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Modern Rheumatology 2009 19 5 542 549 2-s2.0-70350003692 10.1007/s10165-009- 0200-2
18. Hamuryudan V., Ozyazgan Y., Hizli N., Mat C., Yurdakul S., Tüzün Y., Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis & Rheumatology 1997 40 769 774 (Pubitemid 127744665)
19. Yazici H., Pazarli H., Barnes C. G., Tüzün Y., Ozyazgan Y., Silman A., A controlled trial of azathioprine in Behçet's syndrome. The New England Journal of Medicine 1990 322 281 285 (Pubitemid 20046329)
20. Ozyazgan Y., Yurdakul S., Yazici H., Tüzün B., Işçimen A., Tüzün Y., Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. British Journal of Ophthalmology 1992 76 241 243
21. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., Inaba G., Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. The Lancet 1989 1 8647 1093 1096 2-s2.0-0024565498 (Pubitemid 19128039)
22. Hamuryudan V., Mat C., Saip S., Özyazgan Y., Siva A., Yurdakul S., Zwingenberger K., Yazici H., Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1998 128 6 443 450 2-s2.0-0032520803
23. Davatchi F., Shams H., Shahram F., Nadji A., Chams-Davatchi C., Sadeghi Abdollahi B., Faezi T., Akhlaghi M., Ashofteh F., Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years. International Journal of Rheumatic Diseases 2013 16 5 568 577 2-s2.0-84879631646 10.1111/1756-185X.12139
24. Davatchi F., Sadeghi Abdollahi B., Shams H., Shahram F., Nadji A., Chams-Davatchi C., Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behçet's disease: longitudinal study of up to 10 years. International Journal of the Rheumatic Diseases 2013 10.1111/1756-185X.12248
25. Davatchi F., Shahram F., Chams H., Jamshidi A. R., Nadji A., Chams C., Akbarian M., Gharibdoost F., High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Advances in Experimental Medicine and Biology 2003 528 579 584 2-s2.0-0642338779
26. Hamuryudan V., Yurdakul S., Moral F., Numan F., Tüzün H., Tüzüner N., Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. British Journal of Rheumatology 1994 33 48 51 (Pubitemid 24042036)
27. Hamuryudan V., Er T., Seyahi E., Akman C., Tüzün H., Fresko I., Pulmonary artery aneurysms in Behçet syndrome. The American Journal of Medicine 2004 117 867 870 (Pubitemid 39602798)
28. Kural-Seyahi E., Fresko I., Seyahi N., Ozyazgan Y., Mat C., Hamuryudan V., Yurdakul S., Yazici H., The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003 82 1 60 76 2-s2.0-0037246320 10.1097/00005792-200301000-00006 (Pubitemid 36139801)
29. Calamia K. T., Schirmer M., Melikoglu M., Major vessel involvement in Behçet's disease: an update. Current Opinion in Rheumatology 2011 23 1 24 31 2-s2.0-78650515115 10.1097/BOR.0b013e3283410088
30. Al-Araji A., Kidd D. P., Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. The Lancet Neurology 2009 8 2 192 204 2-s2.0-58249144864 10.1016/S1474-4422(09)70015-8
31. Kötter I., Zierhut M., Eckstein A. K., Vonthein R., Ness T., Günaydin I., Grimbacher B., Blaschke S., Meyer-Riemann W., Peter H. H., Stübiger N., Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. British Journal of Ophthalmology 2003 87 4 423 431 2-s2.0-0345701528 10.1136/bjo.87.4.423 (Pubitemid 36399030)
32. Seider N., Beiran I., Scharf J., Miller B., Intravenous immunoglobulin therapy for resistant ocular behçet's disease. British Journal of Ophthalmology 2001 85 11 1287 1288 2-s2.0-0034748411 10.1136/bjo.85.11.1287 (Pubitemid 33016103)
33. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., Basaran E., Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Archives of Dermatology 2002 138 4 467 471 2-s2.0-0036217303 (Pubitemid 34290024)
34. Zhou Z. Y., Chen S. L., Shen N., Lu Y., Cytokines and Behcet's Disease. Autoimmunity Reviews 2012 11 10 699 704 2-s2.0-84864389634 10.1016/j.autrev. 2011.12.005
35. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., Hamuryudan V., Yazici H., Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. Journal of Rheumatology 2005 32 1 98 105 2-s2.0-11844283956 (Pubitemid 40092599)
36. Perra D., Alba M. A., Callejas J. L., Mesquida M., Ríos- Fernández R., Adán A., Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012 51 1825 1831
37. Sfikakis P. P., Kaklamanis P. H., Elezoglou A., Katsilambros N., Theodossiadis P. G., Papaefthimiou S., Markomichelakis N., Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-Behçet disease. Annals of Internal Medicine 2004 140 5 404 406 2-s2.0-1442357109 (Pubitemid 38268925)
38. Mesquida M., Victoria Hernández M., Llorenç V., Pelegrín L., Espinosa G., Dick A. D., Behçet disease-associated uveitis successfully treated with golimumab. Ocular Immunology and Inflammation 2013 21 160 162
39. Cantini F., Niccoli L., Nannini C., Kaloudi O., Cassarà E., Susini M., Lenzetti I., Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics: Targets and Therapy 2012 6 5 12 2-s2.0-84856726561
40. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Hanami K., Tanaka Y., Efficacy of combination therapy of anti-TNF- antibody infliximab and methotrexate in refractory entero-Behçet's disease. Modern Rheumatology 2011 21 2 184 191 2-s2.0-79960139513 10.1007/s10165-010-0370-y
41. Pipitone N., Olivieri I., Padula A., D'Angelo S., Nigro A., Zuccoli G., Boiardi L., Salvarani C., Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Care and Research 2008 59 2 285 290 2-s2.0-39449127014 10.1002/art.23345 (Pubitemid 351272967)
42. Borhani Haghighi A., Safari A., Nazarinia M. A., Habibagahi Z., Shenavandeh S., Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clinical Rheumatology 2011 30 7 1007 1012 2-s2.0-79959591365 10.1007/s10067-011-1726-1
43. Botsios C., Sfriso P., Furlan A., Punzi L., Dinarello C. A., Resistant Behçet disease responsive to anakinra. Annals of Internal Medicine 2008 149 4 284 286 2-s2.0-49849103750
44. Bilginer Y., Ayaz N. A., Ozen S., Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clinical Rheumatology 2010 29 2 209 210 2-s2.0-77949884645 10.1007/s10067-009-1279-8
45. Gül A., Tugal-Tutkun I., Dinarello C. A., Reznikov L., Esen B. A., Mirza A., Scannon P., Solinger A., Interleukin-1 β -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Annals of the Rheumatic Diseases 2012 71 4 563 566 2-s2.0-84857922054 10.1136/annrheumdis- 2011-155143
46. Ugurlu S., Ucar D., Seyahi E., Hatemi G., Yurdakul S., Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. Annals of the Rheumatic Diseases 2012 71 9 1589 1591 2-s2.0-84867410710
47. Emmi G., Silvestri E., Cameli A. M., Bacherini D., Vannozzi L., Squatrito D., Anakinra for resistant Behçet uveitis: why not? Clinical and Experimental Rheumatology 2013 31 152 153
48. Caso F., Rigante D., Vitale A., Lucherini O. M., Cantarini L., Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clinical and Experimental Rheumatology. In press
49. Cantarini L., Vitale A., Borri M., Galeazzi M., Franceschini R., Successful use of canakinumab in a patient with resistant Behçet's disease. Clinical and Experimental Rheumatology 2012 30 72, article S115 2-s2.0-84874983325
50. Vitale A., Rigante D., Caso F., Brizi M. G., Galeazzi M., Costa L., Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of Behçet's disease patients. Dermatology 2014 228 3 10.1159/000358125
51. Hirano T., Ohguro N., Hohki S., Hagihara K., Shima Y., Narazaki M., Ogata A., Yoshizaki K., Kumanogoh A., Kishimoto T., Tanaka T., A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology 2012 22 2 298 302 2-s2.0-84861483650 10.1007/s10165-011-0497-5
52. Shapiro L. S., Farrell J., Borhani Haghighi A., Tocilizumab treatment for neuro-Behcet's disease, the first report. Clinical Neurology and Neurosurgery 2012 114 3 297 298 2-s2.0-84857783564 10.1016/j.clineuro.2011.10.024
53. Urbaniak P., Hasler P., Kretzschmar S., Refractory neuro-Behçet treated by tocilizumab: a case report. Clinical and Experimental Rheumatology 2012 30 supplement 72 S73 S75 2-s2.0-84873260003
54. Caso F., Iaccarino L., Bettio S., Ometto F., Costa L., Punzi L., Doria A., Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunologic Research 2013 56 2-3 390 397 2-s2.0-84879555336 10.1007/s12026-013-8411-1
55. Redondo-Pachón M. D., Enríquez R., Sirvent A. E., Andrada E., Noguera-Pons R., Millán I., Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet's disease. Renal Failure 2013 35 547 550
56. Diamantopoulos A. P., Hatemi G., Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of two cases. Rheumatology (Oxford) 2013 52 1923 1924
57. Baerveldt E. M., Kappen J. H., Thio H. B., Van Laar J. A. M., Martin Van Hagen P., Prens E. P., Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa. Annals of the Rheumatic Diseases 2013 72 4 626 627 2-s2.0-84874438697 10.1136/annrheumdis-2012-202392
58. Sadreddini S., Noshad H., Molaeefard M., Noshad R., Treatment of retinal vasculitis in Behçt's disease with rituximab. Modern Rheumatology 2008 18 3 306 308 2-s2.0-46549090127 10.1007/s10165-008-0057-9
59. Davatchi F., Shams H., Rezaipoor M., Sadeghi-Abdollahi B., Shahram F., Nadji A., Chams-Davatchi C., Akhlaghi M., Faezi T., Naderi N., Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases 2010 13 3 246 252 2-s2.0-77955356607 10.1111/j.1756-185X.2010.01546.x
60. Zhao B. H., Oswald A. E., Improved clinical control of a challenging case of Behçet's disease with rituximab therapy. Clinical Rheumatology 2014 33 149 150
61. Dinarello C. A., van der Meer J. W., Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology 2013 25 6 469 484 10.1016/j.smim.2013.10.008
62. Caso F., Rigante D., Vitale A., Lucherini O. M., Costa L., Atteno M., Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. International Journal of Rheumatology 2013 2013 15 513782 10.1155/2013/513782
63. Moll M., Kuemmerle-Deschner J. B., Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology 2013 147 3 242 275 2-s2.0-84877763412 10.1016/j.clim.2013.04.008
64. Hamzaoui K., Hamaz M., Ayed K., Production of TNF-alpha and IL-1 in active Behçet's disease. The Journal of Rheumatology 1990 17 1428 1429 (Pubitemid 20382885)
65. Pay S., Erdem H., Pekel A., Simsek I., Musabak U., Sengul A., Dinc A., Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1 β play a major role in Behçet's synovitis? Rheumatology International 2006 26 7 608 613 2-s2.0-33645865276 10.1007/s00296-005-0040-0
66. Fonseca J. E., Santos M. J., Canhão H., Choy E., Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmunity Reviews 2009 8 7 538 542 2-s2.0-67349104400 10.1016/j.autrev.2009.01.012
67. Akman-Demir G., Tüzün E., Içöz S., Yeşilot N., Yentür S. P., Kürtüncü M., Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 2008 44 373 366
68. Vaitla P. M., Radford P. M., Tighe P. J., Powell R. J., McDermott E. M., Todd I., Drewe E., Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism 2011 63 4 1151 1155 2-s2.0-79953689919 10.1002/art.30215
69. Woodrick R. S., Ruderman E. M., IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. Bulletin of the NYU Hospital for Joint Diseases 2012 70 3 195 199 2-s2.0-84869425250
70. Chi W., Zhu X., Yang P., Liu X., Lin X., Zhou H., Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Investigative Ophthalmology & Visual Science 2008 49 3058 3064
71. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., Ayed K., Cytokine profile in Behçet's disease patients: relationship with disease activity. Scandinavian Journal of Rheumatology 2002 31 4 205 210 2-s2.0-0036351437 10.1080/030097402320318387 (Pubitemid 34971876)
72. Xavier J. M., Shahram F., Davatchi F., Rosa A., Crespo J., Abdollahi B. S., Nadji A., Jesus G., Barcelos F., Patto J. V., Shafiee N. M., Ghaderibarim F., Oliveira S. A., Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet's disease. Arthritis & Rheumatology 2012 64 2761 2772
73. Mizuki N., Meguro A., Ota M., Ohno S., Shiota T., Kawagoe T., Ito N., Kera J., Okada E., Yatsu K., Song Y.-W., Lee E.-B., Kitaichi N., Namba K., Horie Y., Takeno M., Sugita S., Mochizuki M., Bahram S., Ishigatsubo Y., Inoko H., Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nature Genetics 2010 42 8 703 706 2-s2.0-77955091234 10.1038/ng.624
74. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K. P., Vega F., To W., Wagner J., O'Farrell A.-M., McClanahan T., Zurawski S., Hannum C., Gorman D., Rennick D. M., Kastelein R. A., De Waal Malefyt R., Moore K. W., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R β 1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology 2002 168 11 5699 5708 2-s2.0-0036604306 (Pubitemid 34556153)
75. Gottlieb A., Menter A., Mendelsohn A., Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. The Lancet 2009 373 633 640 2-s2.0-78149286841
76. Ekşiolu-Demiralp E., Kibarolu A., Direskeneli H., Yavuz Ş., Karsli F., Yurdakul S., Yazici H., Akolu T., Phenotypic characteristics of B cells in Behcet's disease: increased activity in B cell subsets. Journal of Rheumatology 1999 26 4 826 832 2-s2.0-2542507876 (Pubitemid 29195669)
77. Suh C. H., Park Y. B., Song J., Lee C. H., Lee S. K., Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet's disease. Arthritis & Rheumatology 2001 44 1707 1712 (Pubitemid 32642234)
78. Hamzaoui A., Chelbi H., Sassi F. H., Hamzaoui K., Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement. Oxidative Medicine and Cellular Longevity 2010 3 2 122 128 2-s2.0-77953688927 10.4161/oxim.3.2.11149
79. Hirohata S., Kikuchi H., Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behçet's disease. Clinical and Experimental Rheumatology 2009 27 S91 S95
80. Leget G. A., Czuczman M. S., Use of rituximab, the new FDA-approved antibody. Current Opinion in Oncology 1998 10 6 548 551 2-s2.0-0031785720 (Pubitemid 28502249)
81. Edwards J. C. W., Szczepański L., Szechiński J., Filipowicz-Sosnowska A., Emery P., Close D. R., Stevens R. M., Shaw T., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine 2004 350 25 2572 2581 2-s2.0-2942537697 10.1056/NEJMoa032534 (Pubitemid 38758544)
82. Andrade-Ortega L., Irazoque-Palazuelos F., Muñóz- López S., Rosales-Don Pablo V. M., Efficacy and tolerability of rituximab in patients with rhupus. Reumatologia Clinica 2013 9 4 201 205 2-s2.0-84879887049 10.1016/j.reuma.2012.10.010
83. Caso F., Fiocco U., Costa L., Sfriso P., Punzi L., Doria A., Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine 2014 81 2 190 192 2-s2.0-84881048472 10.1016/j.jbspin.2013.07.011
84. Shin J. I., Eisenhut M., A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion? Journal of Allergy and Clinical Immunology 2014 133 2, article 600 10.1016/j.jaci.2013.11.022
85. Kötter I., Hamuryudan V., Oztürk Z. E., Yazici H., Interferon therapy in rheumatic diseases: state-of-the-art 2010. Current Opinion in Rheumatology 2010 22 278 283
86. Direskeneli H., Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology 2006 45 12 1461 1465 2-s2.0-33751435160 10.1093/rheumatology/kel329 (Pubitemid 44817050)
87. Vitale A., Rigante D., Lucherini O. M., Caso F., Muscari I., Magnotti F., Brizi M. G., Guerrini S., Patti M., Punzi L., Galeazzi M., Cantarini L., Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators of Inflammation 2013 2013 16 2-s2.0-84881453312 10.1155/2013/939847 939847